on HYBRIGENICS (EPA:ALHYG)
PIMS Technology secures €500,000 in funding from Bpifrance
PIMS Technology, a subsidiary of ATON SA, has obtained €500,000 in funding from Bpifrance to develop its patient stratification technology, PIMS® (Physiological Inter-Molecular Modulation Spectroscopy). This financial support, in the form of a repayable advance, is in addition to €150,000 in grants already awarded. PIMS, a spin-off of Inoviem Scientific, also benefits from support from Capital Grand Est and Weil Industries.
The company's PIMS® Q8 platform enables predictive patient analytics to improve treatment effectiveness and optimize clinical trials. PIMS is preparing a funding round to accelerate its commercialization beyond oncology. This fundraising strengthens PIMS's position in the precision medicine sector.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all HYBRIGENICS news